MUSTANG BIO INC (MBIO)

Company Profile

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Worcester Massachusetts, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2017-08-22. The firm is focused on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The Company’s pipeline is focused on three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The firm is developing CAR T therapies for hematologic malignancies in partnership with the City of Hope National Medical Center (COH) targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutchinson Cancer Center (Fred Hutch) targeting CD20 (MB-106). The company is also developing CAR T therapies for solid tumors in partnership with COH targeting IL13Ra2 (MB-101), HER2 (MB-103), and PSCA (MB-105).

Company Info

MUSTANG BIO INC

377 Plantation Street

Worcester Massachusetts MASSACHUSETTS 01605

P: 17816524500

CEO: Manuel Litchman

Employees: 113

Website: https://www.mustangbio.com/